Kromek Group (KMK) H2 2026 Pre-Recorded earnings summary
Event summary combining transcript, slides, and related documents.
H2 2026 Pre-Recorded earnings summary
18 Sep, 2026Executive summary
Fiscal 2026 revenue reached GBP 27.1 million, in line with market expectations, driven by strong growth in both advanced imaging and CBRN detection segments.
Underlying business growth was 36% year-over-year, supporting continued expansion into fiscal 2027.
Profit before tax was GBP 2.5 million, exceeding market expectations.
The business is positioned for further growth, with a robust pipeline and confidence in delivering on future guidance.
Financial highlights
Revenue of GBP 27.1 million, with advanced imaging and CBRN detection both contributing to growth.
Underlying margins maintained despite a reduction in gross margin due to lower enablement contract revenue.
Profit before tax at GBP 2.5 million; adjusted EPS at 0.4, down from 0.5 last year due to reduced enablement revenue.
Net debt at year-end was GBP 1.5 million, with an additional GBP 1 million cash received post year-end.
Cash generated from operations exceeded GBP 3 million; net cash from financing was GBP 4.5 million.
Outlook and guidance
Confident in delivering results in line with market expectations for fiscal 2027.
Expecting margins to return to mid-50s (excluding enablement revenue) as product mix normalizes.
Anticipate continued growth in both advanced imaging and CBRN detection segments.
Biosecurity segment expected to enter commercial phase, with consumable-driven revenue model.
Latest events from Kromek Group
- Underlying growth in both divisions and a strong order book support a positive FY 2027 outlook.KMK
H2 2026 (Q&A) - FY26 revenues and PBT in line with expectations, with strong growth in both core divisions.KMK
H2 2026 TU - Profitability and margin growth achieved as revenue hit £15.0m, targeting £60m and 30% EBITDA.KMK
H1 2026 - Siemens deal, rising margins, and strong contracts underpin profitable growth and ambitious targets.KMK
H2 2025 - FY25 brings >30% revenue growth, first positive PBT, and ambitious midterm financial targets.KMK
CMD Q&A 2025 - FY25 marks a shift to profitability and >30% revenue growth, targeting >£60M revenue midterm.KMK
CMD 2025 - Record revenue, positive EBITDA, and strong contract wins drive confident growth outlook.KMK
H2 2024 - FY 2025 revenue and profit to exceed expectations, underpinned by strategic partnerships.KMK
Trading Update - Siemens Healthineers deal and margin gains set the stage for profitability in FY 2025.KMK
H1 2025